Breaking News Headlines Today | Ground News

See every side of every news story

Times Argus image

News from Times Argus

The Ground News media bias check for Times Argus is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and All Sides.

Times Argus’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about Times Argus

Where is Times Argus located?Times Argus's Website Times Argus's Twitter Times Argus's Wikipedia

Media Bias Ratings

Average Bias Rating:

Center

Center

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top Times Argus News

Open Cooperation Forum at China International Fair for Trade in Services 2025 Held — REUTERS / pwu404

China Economy · China

Open Cooperation Forum at China International Fair for Trade in Services 2025 Held

61% Center coverage: 36 sources

National Grid and Emerald AI Announce Strategic Partnership to Demonstrate AI Power Flexibility in the UK

Artificial Intelligence · United Kingdom

National Grid and Emerald AI Announce Strategic Partnership to Demonstrate AI Power Flexibility in the UK

54% Center coverage: 26 sources

National Grid and Emerald AI are partnering to show how AI data centres can support a smarter, more flexible grid.A UK-first live trial is planned for late 2025 on a grid connected data centre using Emerald AI's platform and cutting-edge…See the Story

Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma

Hong Kong City · Hong Kong

Akeso Announces First Patient Dose in Global Registrational Trial of Cadonilimab (PD-1/CTLA-4) for PD-1 Treatment-Resistant Hepatocellular Carcinoma

48% Center coverage: 25 sources

HONG KONG, Sept. 15, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its global, multicenter, randomized Phase II registrational trial (COMPASSION-36/AK104-225). The trial will evaluate cadonilimab, Akeso's first-in-class PD-1/CTLA-4…See the Story

Breaking News Topics Related to Times Argus